# A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

> **NCT06839066** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 70 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)

## Interventions

- **DRUG:** HLX43 DOSE 1
- **DRUG:** HLX43 DOSE 2
- **DRUG:** HLX43 DOSE 3

## Key facts

- **NCT ID:** NCT06839066
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2026-11-22
- **Final completion:** 2027-11-22
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06839066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06839066, "A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06839066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*